New dug price reeval standards will be set within the year

that reference overseas drug price…will cut price of expensive drugs starting next year

HIRA “Will secure the financial sustainability of Korea’s health insurance by managing drugs with higher listed prices than foreign countries”

The Health Insurance Review and Assessment Service said, “We will prepare a final plan within this year” to an inquiry on the progress made on the reevaluation of off-patent drugs through a comparison of overseas drug prices.

 

In particular, based on the established reevaluation standards, HIRA also expressed their intention to sequentially carry out reevaluations starting next year and reduce the prices of drugs listed at higher prices compared to overseas to secure the financial sustainability of Korea’s national health insurance.

 

Such will were found in the response submitted to answer People Power Party Rep.

 

Young-Hee Choi’s written inquiry during the NA audit on the 25th.

 

Regarding the comparison of overseas drug prices, HIRA explained that it had improved the foreign drug price reference standard (foreign drug price conversion formula) through the operation of a working group with the pharmaceutical industry last year.

 

HIRA is currently working with the Ministry of Health and Welfare to prepare a plan to compare and reevaluate overseas drug prices of listed drugs and announced that it will prepare a final plan within this year after gathering opinions through meetings with the pharmaceutical industry.

 

HIRA said, “We plan to carry out the revaluations sequentially on an annual basis starting next year.

 

We will secure the sustainability of health insurance finances by managing the expenditures spent on drugs listed at a higher price compared to foreign countries.”